Global Autoinjectors Market (5th Edition): Industry Trends and Global Forecasts, till 2035

Global Autoinjectors Market (5th Edition): Industry Trends and Global Forecasts, till 2035

The Global Autoinjector Market is valued at USD 90.6 billion in 2024 growing at a CAGR of 6.2% during the forecast period 2024-2035.

Autoinjectors are self-injection devices inbuilt to deliver a specific dose of a drug / therapeutic substance with a simple push of a button. They are spring-loaded syringes working on several mechanisms (ranging from simple push-on-skin devices to fully automated button activated technologies) and include pre-measured medication, thereby, eliminating the need to draw medication from a separate vial, thus resolving various injection-related compliance issues faced by the patients.

The Global Autoinjectors Market is driven by a growing demand for self-administration devices largely due to the increasing chronic conditions such as asthma, diabetes, multiple sclerosis and rheumatoid arthritis. Moreover, these conditions have also been adding to the increasing healthcare burden. A study conducted in the year 2022 reveals that there are around 133 million individuals suffering from one or more chronic illness within the US alone, wherein the predicted value by 2030, is 177 million. The market insights reveal that the treatment of chronic diseases in the hospitals involves intensive care and costs more than USD 1,500 billion per year with additional expenses throughout an individual’s lifetime. The frequent need to take the medication, necessitating regular hospital visits, contributes to the major share of the expenses incurred by patients suffering from chronic diseases. In addition, the reluctance of individuals to receive injections in a clinical setting due to privacy concerns and discomfort complements the challenges for healthcare providers, compromising the treatment process.

Hence, the above-mentioned challenges are addressed by various self-administering drug delivery systems, such as prefilled syringes, large volume wearable injectors, needle free jet injectors, turning out to be a breakthrough. These drug delivery devices impart greater independence, eliminating the dependence on healthcare providers for drug administration, leading to reduced healthcare costs. However, these drug delivery systems possess certain limitations, such as skin sensitivity issues, manual needle insertion, and needle stick injuries, thereby creating the need for better administration solutions.

Because of the insufficiency of the conventional drug delivery systems, the rapid gaining performance of autoinjectors is worth noticing, specifically in the immediate treatment of emergency situations, such as anaphylactic shocks, strokes and rheumatoid arthritis. In addition, the audio-visual features in some of the autoinjectors allow the patient to remove the device from the skin, on completion of dose. The growing adoption of self-administration devices and ongoing advancements in the technologies (focused on integrated needle safety, Bluetooth connectivity and monitoring of historical injection logs), tends to create a growing market of Autoinjectors henceforth.



Key Market Segments

Usability of Autoinjectors

• Disposable Autoinjector
• Reusable Autoinjector

Route of Administration

• Subcutaneous
• Intramuscular
• Intravenous

Type of Molecule Delivered

• Proteins
• Antibodies
• Peptides
• Small molecules
• Others

Type of Actuation Mechanism

• Manual
• Automatic

Volume of Container

• Less than 1 ml
• 1-2 ml
• More than 2 ml

End User

• Home Care
• Hospitals and Clinics
• Ambulatory Surgical Centers

Target Indication

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Weight Loss
• Anaphylaxis
• Migraine
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

Research Coverage:

• The chapter gives an overview of various self-administrable devices for drug delivery, specifically focusing on autoinjectors. The chapter provides information on the progression of autoinjectors, along with related details such as, their individual components, device categories and associated manufacturing / packaging processes. It also discusses the advantages of autoinjectors that have led to their growing adoption over the last several years along with the existing concerns related to needlestick injuries and the various preventive laws that have been passed worldwide, for addressing the pressing need for introducing advanced safety features in such devices. In addition, it also includes a discussion on the prospects of this industry.
• The chapter also discusses about the various types of primary drug containers that are utilized in autoinjectors. It demonstrates information on current trends related to the use of prefilled syringes, cartridges and vials. In addition, enlistment the diverse types of primary drug containers that are available in the market, along with details on companies that are involved in the production of such containers is also included in the chapter.
• A thorough analysis of current market landscape of autoinjectors based on several relevant parameters, such as status of development (commercialized and under development), usability (disposable autoinjector and reusable autoinjector), type of primary drug container (cartridges, syringes and vials), requirement of needle, volume of container (less than 1 mL, 1 to 2 mL, 2.1 to 5 mL and more than 5 mL), type of dose delivered (fixed dose and variable dose), route of administration (intramuscular, subcutaneous and unspecified / others), type of actuation mechanism (manual and automatic), type of feedback mechanism (audible and visual), availability of connectivity feature, target indication (diabetes, multiple sclerosis, rheumatoid arthritis and others), type of molecule delivered (antibodies, peptides, proteins, small molecules and others) and end user (home care, hospital and clinics, and others). Further, the chapter provides a comprehensive analytical report of autoinjector manufacturers, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, type of company and most active players (in terms of number of autoinjectors manufactured).
• A cross-examined report comprising the market of autoinjectors based on the manufacturer strength (in terms of years of experience and company size) and product strength (in terms of status of development, type of drug container, requirement of needle, volume of container, type of dose delivered, type of actuation mechanism, type of feedback mechanism, number of target indication and number of molecules delivered).
• The report includes a detailed biopsy of the leading autoinjector manufacturers, highlighting the current perceptions regarding their proprietary brands across different device types. It takes into consideration several aspects, such as strength and diversity of product portfolio, routes of administration, type of actuation mechanism, type of feedback mechanism, geographical presence / reach and supplier strength of each player.
• A comprehensive profile of key autoinjector manufacturers (shortlisted based on the number of autoinjectors in their product portfolio). Each profile attributes a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), details related to its financial performance (if available), autoinjectors portfolio, recent developments and an informed future outlook.
• An in-depth analysis of the partnerships inked between stakeholders engaged in this industry, during the period 2019-2023, based on several parameters. These parameters include partnership, type of partnership, type of partner and most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
• The chapter provides a detailed exploration of patents related to autoinjectors, filed / granted, since 2019, based on the type of patent (granted patents, patent applications and others), patent publication year, patent application year, patent jurisdiction, cooperative patent classification (CPC) symbols, type of applicant and most active players (in terms of the number of patents filed). In addition, the chapter includes patent benchmarking and an insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
• The chapter provides a detailed overview encompassing current market landscape of commercialized autoinjectors combination product, such as approval year, usability (disposable autoinjector and reusable autoinjector), type of primary drug container (ampoules, cartridges, syringes and vials), requirement of needle, volume of container (less than 0.5 mL, 0.5 to 1 mL and more than 1 mL), injection time (less than 5 seconds, 5 to 10 seconds and more than 10 seconds), type of dose delivered (fixed and variable), route of administration (intramuscular, intravenous and subcutaneous), type of actuation mechanism (automatic, manual and semi-automatic), type of feedback mechanism (audible and visual), availability of connectivity feature, target indication, severity of indication (acute conditions, chronic conditions and emergency conditions), type of molecule delivered (antibodies, peptides, proteins, small molecules and others), end user (home care setting, hospital and clinics, and others) and target population (adults, geriatric and pediatrics). Further, the chapter provides explanation on commercialized autoinjector combination product manufacturers, along with information on establishment year, company size (in terms of employee count), location of headquarters, type of company and most active players (in terms of number of commercialized autoinjector combination products developed).
• The chapter elucidates a detailed progression of the current market landscape of early and late stage autoinjectors combination product, such as stage of development (preclinical, clinical, NDA submitted and NDA approved), route of administration (intramuscular, subcutaneous and unspecified / others), dose strength, target indication, severity of indication (acute conditions, chronic conditions and emergency conditions), type of molecule delivered (antibodies, peptides, proteins, small molecules and others), end user (home care setting and hospital and clinics), target population (adults, geriatric and pediatrics) and gender of target population (male and female). Moreover, the chapter also clarifies details on manufacturers, along with information on year of establishment, company size (in terms of employee count), location of headquarters and type of company.
• Comprehensive set of profiles of the key players (shortlisted based on the number of commercialized combination products in their product portfolio) that are engaged in the autoinjector combination products domain. Each profile provides an insight of the company (including information on year of establishment, location of headquarters, number of employees and leadership team) and information on its autoinjector product portfolio.
• A detailed analyzed evaluation highlighting the key opinion leaders (KOLs) in this domain, based on several relevant factors, such as role of KOL, type of sponsor organization, affiliated organization, target indication and location of clinical trials. In addition, the chapter highlights the most prominent KOLs, based on our proprietary scoring criteria.
• An epitome on the most targeted indications covering detailed explication of the approved autoinjector combination products.
• A case study converged on the role of medical device CMOs in the manufacturing and assembly of drug-delivery devices, including autoinjectors. It enlists service providers with details on their operational scale and types of services provided for device production.
• An intricate case history of prefilled syringes that either fall into the category of commercialized or under development. It includes an itemized description of the prefilled syringes, based on several relevant dynamics, such as, type of barrel fabrication material, number of barrel chambers and type of needle system. Further, the chapter provides a detailed analysis of prefilled syringe manufacturers, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters.
• An enumerated report on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of autoinjectors market; it includes a Harvey ball analysis, underlining the relative impact of each SWOT parameter on industry dynamics.
• A substantial report on the autoinjectors market forecast analysis to estimate the existing market size and future opportunity in the market, till the year 2035. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also comprehends the likely distribution of the current and forecasted opportunity within the autoinjector market. Moreover, accounting for future uncertainties and to adding robustness to our model, three forecast scenarios have been provided, namely conservative, base, and optimistic scenarios, targeting different tracks of the industry’s growth.
• An insightful projection of the current and future opportunity within the autoinjectors market across usability, such as disposable autoinjectors and reusable autoinjector.
• Detailed projections of the current and future opportunity within the auto injector market size across several types of dynamics, which include route of administration, such as intramuscular, intravenous and subcutaneous, the type of molecule, such as antibodies, peptides, proteins, small molecules and others, type of actuation mechanism, such as manual and automatic, volume of container, such as less than 1 mL, 1-2 mL and more than 2 mL, various end user, such as ambulatory surgical centers, home care and hospitals and clinics.
• An in-depth insightful projection of the current and future opportunity within the autoinjector market across target indication, such as anaphylaxis, diabetes, migraine, multiple sclerosis, rheumatoid arthritis, weight loss and other indications.
• A comprehensive report carrying details about the projections of the current and future opportunity within the autoinjectors market key across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the Global Autoinjectors Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

• Amgen
• Antares Pharma
• ChemProtect.SK
• Elcam Medical
• Eli Lilly and Company
• Jiangsu Delfu Medical Device
• Kindeva Drug Delivery
• Merck
• Novartis
• Novo Nordisk
• Oval Medical Technologies
• Owen Mumford
• PreciHealth
• Recipharm
• Sanofi
• SHL Medical
• Teva Pharmaceuticals
• Union Medico
• Ypsomed